ESR1 and breast cancer: In BC, ANXA9 was reported to be associated with estrogen receptor 1 (ER1) and can be upregulated by estrogen receptor beta (ERβ), which correlates with BC bone metastasis [6, 7], rendering it a potentially valuable target for BC [8].